Dynamic42 and EPO (Experimental Pharmacology and Oncology) announced a collaboration to bring organ-on-chip platforms earlier into preclinical glioblastoma workflows. The partners will pair Dynamic42’s human BBB-on-chip with EPO’s translational oncology experience and tumor models, focusing on how human versus non-human blood–brain barrier biology influences therapeutic response. The first joint projects target glioblastoma and the blood–brain barrier, aiming to reduce the risk of late-stage failures driven by preclinical data that do not reflect human physiology. Both groups plan to present early results at the American Association for Cancer Research Annual Meeting 2026. For drug developers, the deal signals continued industry investment in “human-relevant” in vitro systems that can generate more decision-grade evidence before animal studies.